Literature DB >> 14344952

[TREATMENT OF PAROXYSMAL TACHYCARDIAS. OUR EXPERIENCE WITH ANTAZOLINE].

M MUNIZ, A J BELLINI.   

Abstract

Entities:  

Keywords:  ANTIHISTAMINICS; DRUG THERAPY; TACHYCARDIA, PAROXYSMAL

Mesh：

Substances：

Year:  1965        PMID： 14344952

Source DB:  PubMed          Journal:  Folha Med        ISSN： 0015-5454


× No keyword cloud information.
  2 in total

1.  Intravenous antazoline, a first-generation antihistaminic drug with antiarrhythmic properties, is a suitable agent for pharmacological cardioversion of atrial fibrillation induced during pulmonary vein isolation due to the lack of influence on atrio-venous conduction and high clinical effectiveness (AntaEP Study).

Authors:  Michal M Farkowski; Aleksander Maciag; Ilona Kowalik; Marek Konka; Hanna Szwed; Mariusz Pytkowski
Journal:  Br J Clin Pharmacol       Date:  2019-05-23       Impact factor: 4.335

2.  Clinical efficacy of antazoline in rapid cardioversion of paroxysmal atrial fibrillation--a protocol of a single center, randomized, double-blind, placebo-controlled study (the AnPAF Study).

Authors:  Michal M Farkowski; Aleksander Maciag; Rafal Dabrowski; Mariusz Pytkowski; Ilona Kowalik; Hanna Szwed
Journal:  Trials       Date:  2012-09-11       Impact factor: 2.279
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.